The latest update is out from Telix Pharmaceuticals ( (AU:TLX) ).
Telix Pharmaceuticals announced the resignation of Anne Whitaker from its board due to personal and family reasons, effective immediately. This resignation impacts the upcoming Annual General Meeting as her nomination for election has been withdrawn, but it does not affect the validity of proxy forms for the meeting. The company expressed regret over her departure and extended best wishes for her future endeavors.
More about Telix Pharmaceuticals
Telix Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, the company operates internationally in the United States, Brazil, Canada, Europe, and Japan. Telix focuses on addressing significant unmet medical needs in oncology and rare diseases with a portfolio of clinical and commercial stage products.
YTD Price Performance: 34.84%
Average Trading Volume: 5,025
Technical Sentiment Signal: Sell
Current Market Cap: $6.16B
See more data about TLX stock on TipRanks’ Stock Analysis page.